Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Aigen Investment Management LP

Aigen Investment Management LP trimmed its position in Xencor, Inc. (NASDAQ:XNCR) by 7.2% in the third quarter, Holdings Channel reports. The firm owned 13,670 shares of the biopharmaceutical company’s stock after selling 1,064 shares during the quarter. Aigen Investment Management LP’s holdings in Xencor were worth $275,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of XNCR. Quarry LP acquired a new position in shares of Xencor in the 2nd quarter worth approximately $36,000. SG Americas Securities LLC acquired a new position in Xencor in the second quarter worth $154,000. XTX Topco Ltd bought a new stake in Xencor during the second quarter valued at $196,000. Acadian Asset Management LLC acquired a new stake in shares of Xencor during the first quarter worth $206,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Xencor in the 2nd quarter worth about $212,000.

Insider Activity

In other news, CEO Bassil I. Dahiyat sold 3,366 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $24.02, for a total transaction of $80,851.32. Following the completion of the sale, the chief executive officer now owns 352,615 shares in the company, valued at approximately $8,469,812.30. This represents a 0.95 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP John R. Desjarlais sold 68,684 shares of Xencor stock in a transaction on Monday, November 11th. The stock was sold at an average price of $23.48, for a total value of $1,612,700.32. Following the completion of the transaction, the vice president now owns 200,104 shares in the company, valued at $4,698,441.92. The trade was a 25.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.23% of the company’s stock.

Xencor Trading Down 1.8 %

NASDAQ:XNCR opened at $23.07 on Friday. The business has a fifty day moving average of $21.12 and a 200-day moving average of $20.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor, Inc. has a 1 year low of $15.31 and a 1 year high of $26.84.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.27. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $10.70 million during the quarter, compared to analyst estimates of $14.59 million. During the same period in the prior year, the business posted ($0.40) EPS. The business’s revenue for the quarter was down 81.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Xencor, Inc. will post -3.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. BMO Capital Markets reaffirmed an “outperform” rating and set a $34.00 target price (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Royal Bank of Canada boosted their price objective on Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Thursday, September 26th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $38.00 target price on shares of Xencor in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Xencor currently has an average rating of “Moderate Buy” and a consensus target price of $35.75.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.